Role of pharmacoeconomics in developing countries

Amani Mori, Paul Gavaza, Bjarne Robberstad

DOI: https://doi.org/10.7175/fe.v14i1.638

Full Text:

HTML PDF

References

  • WHO: Equitable access to essential medicines: a framework for collective action. Geneva: World Health Organization, 2004
  • WHO: The world medicine situation. Geneva: World Health Organization, 2011
  • Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009; 373: 240-9; http://dx.doi.org/10.1016/S0140-6736(08)61762-6
  • Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. Third edition. New York: Oxford University Press, 2005
  • Hogerzeil HV. The concept of essential medicines: lessons for rich countries. BMJ 2004; 329:1169-1171; http://dx.doi.org/10.1136/bmj.329.7475.1169
  • Mori AT, Robberstad B. Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review. BMC Med Inform Decis Mak 2012; 12: 110; http://dx.doi.org/10.1186/1472-6947-12-110
  • Gavaza P, Rascati KL, Oladapo AO, et al. The State of Health Economic Research in South Africa: A Systematic Review. Pharmacoeconomics 2012, 30: 925-40; http://dx.doi.org/10.2165/11589450-000000000-00000
  • Gavaza P, Rascat KL, Oladapo AO, et al.The State of Health Economic Evaluation Research in Nigeria: A Systematic Review. Pharmacoeconomics 2010, 28: 539-53
  • Gavaza P, Rascati K, Brown C, et al. The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: a review. Current Therapeutic Research 2008; 69: 268-85; http://dx.doi.org/10.1016/j.curtheres.2008.06.005
  • Babar Z, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28: 1069-74; http://dx.doi.org/10.2165/11584890-000000000-00000
  • Pooja RD, Hitesh CS, Rascati KL. Assessing the quality of pharmacoeconomic studies in India: a systematic review. Pharmacoeconomics 2012; 30: 749-62; http://dx.doi.org/10.2165/11590140-000000000-00000
  • Tarn YH, Hu S, Kamae I, et al. Health-care systems and pharmacoeconomic research in Asia-Pacific Region. Value in Health 2008; 1(Supp 1): S137-5; http://dx.doi.org/10.1111/j.1524-4733.2008.00378.x
  • Mori AT, Kaale EA. Priority setting for the implementation of artemisinin-based combination therapy policy in Tanzania: evaluation against the accountability for reasonableness framework. Implement Sci 2012; 7: 18; http://dx.doi.org/10.1186/1748-5908-7-18
  • Wiseman V, Kim M, Mutabingwa TK, et al. Cost-effectiveness study of three antimalarial drug combinations in Tanzania. PLoS Med 2006; 3: e373; http://dx.doi.org/10.1371/journal.pmed.0030373
  • Chanda P, Masiye F, Chitah BM, et al. A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia. Malar J 2007; 6: 21
  • Muheki C, McIntyre D, Barnes KI. Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa. Trop Med Int Health 2004; 9: 959-66; http://dx.doi.org/10.1111/j.1365-3156.2004.01292.x
  • Pillay A. Role of pharmacoeconomics in a developing country context. In International Conference on Improving Use of Medicines. Antalya, Turkey, 2011
  • Abdulla S, Goodman C, Coleman P, et al. The costs, effects and cost-effectiveness of changing the first line drug for treatment of malaria in Tanzania. Health Economics and Financing Program working paper 01/2000

Refbacks

  • There are currently no refbacks.




© SEEd srl